{
  "trade_id": "PASS-2026-009",
  "ticker": "RGNX",
  "company": "REGENXBIO Inc.",
  "archetype": "pdufa",
  "decision_date": "2026-01-07",
  "decision": "PASS",
  "reason": "Failed kill screens",

  "event_context": {
    "event_ids": ["EVT-2026-038"],
    "catalyst": "FDA decision on RGX-121 for Hunter Syndrome (MPS II)",
    "date": "2026-02-08",
    "days_to_catalyst": 32
  },

  "market_data": {
    "price_at_decision": 15.60,
    "market_cap_millions": 718,
    "note": "Price estimated from market cap"
  },

  "kill_screen_results": {
    "passed": false,
    "failures": [
      {
        "screen": "PDUFA Financial Health - Cash Runway",
        "threshold_months": 18,
        "actual_months": "~14",
        "status": "FAIL",
        "severity": "high",
        "note": "Guidance states cash funds operations 'into early 2027'. From Jan 2026, this leaves ~14 months of runway. Threshold is 18 months to ensure survival through potential CRL/delay without immediate dilution."
      },
      {
        "screen": "PDUFA Financial Health - Debt/Equity",
        "threshold": 0.75,
        "actual": 1.25,
        "status": "FAIL",
        "severity": "medium",
        "calculation": "Total Debt $268M / Equity $213.7M = 1.25"
      }
    ],
    "passes": [
      {
        "screen": "Market Cap Ceiling",
        "threshold_millions": 50000,
        "actual_millions": 718,
        "status": "PASS"
      },
      {
        "screen": "PDUFA Financial Health - Net Cash Position",
        "threshold": 0,
        "actual_millions": 34,
        "status": "PASS",
        "calculation": "Cash $302M - Debt $268M = +$34M"
      }
    ]
  },

  "financial_summary": {
    "cash_and_equivalents_millions": 302.0,
    "total_debt_millions": 268.1,
    "shareholders_equity_millions": 213.7,
    "burn_rate_ttm_millions": 103.3,
    "runway_guidance": "Into early 2027"
  },

  "thesis_assessment": {
    "bull_case": "RGX-121 approval would be transformative and potentially unlock PRV value/milestones, resolving the balance sheet overhang.",
    "bear_case": "Financials are tight. With <18 months runway and high leverage (1.25 D/E), a CRL or delay would be disastrous, likely forcing a highly dilutive raise or restructuring. The framework prioritizes survival safety over binary upside.",
    "framework_view": "Classic 'high risk' PDUFA setup that the kill screens are designed to avoid. Insolvency risk in the bear case is too high."
  },

  "lessons_learned": [
    "Guidance must be measured from the *current* date, not the reporting date.",
    "Potential milestone payments (like PRV) should be excluded from safety runway calculations (conservative basis).",
    "Debt/Equity > 1.0 is a significant red flag for pre-profit biotechs."
  ],

  "tags": [
    "pdufa",
    "biotech",
    "financial_health_fail",
    "high_debt",
    "insufficient_runway"
  ]
}
